| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Dallara Que | Chief Executive Officer, Director | C/O 18000 DEVONSHIRE STREET, NORTHRIDGE | /s/ Bryan F. Kelly, attorney-in-fact | 11 Mar 2026 | 0001756652 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MMED | Performance-Based Restricted Stock Units | Award | +83,334 | $0.000000* | 83,334 | 09 Mar 2026 | Common Stock | 83,334 | Direct | F1, F2 | |||
| transaction | MMED | Employee Stock Option (Right to Buy) | Award | +252,526 | $0.000000* | 252,526 | 09 Mar 2026 | Common Stock | 252,526 | $18.00 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.). |
| F2 | The later of March 9, 2027 or the Divestment Date. |
| F3 | The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030. |